<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Institute of Neurology</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/58CAFD42-4588-4918-9E84-5A6928DADE2E"><gtr:id>58CAFD42-4588-4918-9E84-5A6928DADE2E</gtr:id><gtr:firstName>Alisdair</gtr:firstName><gtr:surname>McNeill</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1001983"><gtr:id>185A3F7A-26A8-44A0-AA01-9DE877AD69FF</gtr:id><gtr:title>Glucocerebrosidase mutations and Parkinson's disease</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G1001983</gtr:grantReference><gtr:abstractText>Parkinson?s disease (PD), a disabling condition which causes tremor, affects 1/150 people in Britain. The causes of PD are not well understood and there is no cure. Recently individuals with Gaucher?s disease (GD) have been shown to have an increased risk of PD. GD is due to glucocerebrosidase gene mutations, which leads to accumulation of fatty substances in the bones and organs. When someone has a mutation in the glucocerebrosidase gene they inherit from their mum and the glucocerebrosidase gene they inherit from dad they develop GD. When someone has just one mutated glucocerebrosidase gene they do not develop GD but are a carrier. GD carriers also have an increased risk of PD. 

Through the national GD clinic we will recruit a group of GD patients and carriers and assess them for early PD. By studying chemical levels in blood and urine of these patients we will identify substances serving as markers of early PD - these will help PD diagnosis. In parallel, we will study cultured skin cells from GD patients, to determine how glucocerebrosidase mutations lead to cell death. This will help identify the cellular processes leading to brain cell death in PD, providing new treatment targets.</gtr:abstractText><gtr:technicalSummary>Parkinson?s disease (PD) is the second most common neurodegenerative disease in the United Kingdom (U.K) with a prevalence of 1/150-1/350. Mutations in glucocerebrosidase (GBA), which cause recessive Gaucher?s disease (GD), have been identified as a key PD risk factor with GD patients having a 24 fold increased risk of PD and heterozygous GBA mutations conferring a 5-10 fold increased risk. Our goal is to investigate the clinical and biochemical features of the PD prodrome in GD patients and GBA mutation carriers, with the following specific and related aims: 

(1) To characterise the clinical features of early PD in GD patients and mutation carriers 
We will ascertain GD patients and GBA mutation carriers at risk of PD through the Royal Free NSCAG funded GD clinic. Subjects will be assessed for non-motor features of early PD (constipation, depression and olfactory dysfunction with the University of Pennsylvania Smell Test) and subtle motor slowing (3m walk, pegboard test and Unified Parkinson?s Disease Rating Scale). 

(2) To identify biochemical markers of PD risk in GD patients and mutation carriers
Blood and urine samples from GD patients and carriers of GBA mutations will be tested for potential biomarkers (urate, anti-oxidants, chitotriosidase, ceramide metabolites). Samples will be taken from GBA carriers aged 30-50 (n=20), aged 50-65 (n=20) and PD patients with GBA mutations (n=20). 

(3) To investigate the cell biology of GBA mutation associated PD 
Our preliminary cell culture data indicates that GBA deficiency causes mitochondrial dysfunction and oxidative stress. In patient derived fibroblasts and SH-SY5Y cells with Sh-RNA knock down of GBA we will study mitochondrial function and oxidative stress with live cell fluorescent imaging. Mitochondrial function will be studied by assessing ATP generation, mitochondrial membrane potential (TMRM fluorescence) and redox state (NADH and flavoprotein autofluorescence). Antioxidant status will be assey measuring aconitase activity and DHE fluorescence. We will study fibroblasts from GD patients without PD (n=5), GD patients with PD (n=5) and mutation carriers with (n=5) and without PD (n=5). 

This project will add to our understanding of the phenotype of PD due to GBA mutations, identify biomarkers of early PD in this group and establish a cohort of patients with early PD for clinical research. The in vitro work will help establish why GBA mutations cause neurodegeneration and illuminate molecular mechanisms of neurodegeneration in sporadic PD.</gtr:technicalSummary><gtr:fund><gtr:end>2013-04-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>147472</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Clinical Medicine</gtr:department><gtr:description>Clinical study of prodromal markers of Parkinson's disease in Gaucher disease families</gtr:description><gtr:id>C11BF9D7-1F45-42DB-83F0-A6C06A19DD9D</gtr:id><gtr:impact>see publications list</gtr:impact><gtr:outcomeId>m6fXs7SGVUa-1</gtr:outcomeId><gtr:partnerContribution>The lysosomal disorders clinic at cambridge provided access to a serties of Gaucehr disease families</gtr:partnerContribution><gtr:piContribution>I was the clinical researcher assessing the patients</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>UK Gaucher disease association</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>558B2BC2-AFE4-401D-BC27-637D9C574D5C</gtr:id><gtr:impact>a short informal piece for the gaucher disease newsletter

nil</gtr:impact><gtr:outcomeId>mbS79jJBsxP</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>9E2A4066-CC6A-4552-8059-D00581D6F125</gtr:id><gtr:title>Hyposmia and cognitive impairment in Gaucher disease patients and carriers.</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb527c8f47b11cfd2bb90849f52723e8"><gtr:id>fb527c8f47b11cfd2bb90849f52723e8</gtr:id><gtr:otherNames>McNeill A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn><gtr:outcomeId>pm_13644_24_22344629</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A347365C-BE4B-4CC5-9F2D-0255CAC8CAE6</gtr:id><gtr:title>Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb527c8f47b11cfd2bb90849f52723e8"><gtr:id>fb527c8f47b11cfd2bb90849f52723e8</gtr:id><gtr:otherNames>McNeill A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>pm_540e177e17701aaf0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1BA744CA-8994-467C-B35D-DC77EB5A93A8</gtr:id><gtr:title>Neuroferritinopathy: update on clinical features and pathogenesis.</gtr:title><gtr:parentPublicationTitle>Current drug targets</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb527c8f47b11cfd2bb90849f52723e8"><gtr:id>fb527c8f47b11cfd2bb90849f52723e8</gtr:id><gtr:otherNames>McNeill A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1389-4501</gtr:issn><gtr:outcomeId>pm_13644_24_22515742</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>16B7DACE-F728-4CEC-AAE2-C1D3FD0DD5E2</gtr:id><gtr:title>Progressive brain iron accumulation in neuroferritinopathy measured by the thalamic T2* relaxation rate.</gtr:title><gtr:parentPublicationTitle>AJNR. American journal of neuroradiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb527c8f47b11cfd2bb90849f52723e8"><gtr:id>fb527c8f47b11cfd2bb90849f52723e8</gtr:id><gtr:otherNames>McNeill A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0195-6108</gtr:issn><gtr:outcomeId>pm_13644_24_22499840</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>96E276FA-17E2-4BAD-8AC5-C3BA17FDE583</gtr:id><gtr:title>A clinical and family history study of Parkinson's disease in heterozygous glucocerebrosidase mutation carriers.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb527c8f47b11cfd2bb90849f52723e8"><gtr:id>fb527c8f47b11cfd2bb90849f52723e8</gtr:id><gtr:otherNames>McNeill A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>pm_13644_24_22577228</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1849372D-EF00-4D7E-835E-2AD025DCAF03</gtr:id><gtr:title>PLA2G6 mutations and other rare causes of neurodegeneration with brain iron accumulation.</gtr:title><gtr:parentPublicationTitle>Current drug targets</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb527c8f47b11cfd2bb90849f52723e8"><gtr:id>fb527c8f47b11cfd2bb90849f52723e8</gtr:id><gtr:otherNames>McNeill A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1389-4501</gtr:issn><gtr:outcomeId>pm_13644_24_22515743</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>67BEA361-17ED-4C5F-8E27-F5BC7EE7A154</gtr:id><gtr:title>Novel pathogenic mutations in the glucocerebrosidase locus.</gtr:title><gtr:parentPublicationTitle>Molecular genetics and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f95aa813f473ac4f55c06f44414f70d4"><gtr:id>f95aa813f473ac4f55c06f44414f70d4</gtr:id><gtr:otherNames>Duran R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1096-7192</gtr:issn><gtr:outcomeId>pm_13644_24_22658918</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F853D9BC-536D-4457-9963-2712D975BE9C</gtr:id><gtr:title>Dopaminergic neuronal imaging in genetic Parkinson's disease: insights into pathogenesis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb527c8f47b11cfd2bb90849f52723e8"><gtr:id>fb527c8f47b11cfd2bb90849f52723e8</gtr:id><gtr:otherNames>McNeill A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_540e176e176f6a677</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1001983</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>